wet age-related macular degeneration
Conditions
Interventions
Intravitreous injection of Beovu(Brolucizumab) for 2 years when needed.
Sponsors
kagawa university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 3)disease duration:regardless 4)Patients who existing anti-VEGF drugs (aflibercept or ranibizumabu) are used, and vitreous injections are performed every 1-3months in the maintenance phase, and exudation dose not improve for 1 year or more(tolerance), who progress vision loss, who relapses immediately without without injection (dependency), and who do not respond to existing anti-VEGF drug therapy from the initial treatment (non responder). 5)BCVA:0.1-1.0 6)Presence of subretinal hemorrhage, scar or macular fibrosis (<50% lesion area) 7)Patient consent:patients who, after receiving a sufficient explanation before participating in this study, obtained their informed consent by themselves. 8)Outpatien
Exclusion criteria
Exclusion criteria: 1) Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2) Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area) 3) Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months) 4) Active intraocular inflammation 5) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 6) Patient who the doctor in charge judges are ineligible for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement rate of visual acuity one year after the change of brolucizumab. | — |
Secondary
| Measure | Time frame |
|---|---|
| One year outcome after the change of brolcizumab:macula dry rate(presence of absence of exudative change), reduction rate of central macular thickness, change rate of subfoveal choroidal thickness, the rate of incidence and enlargement of macular atrophy, and number of administrations | — |
Countries
Japan
Contacts
Public ContactHirokazu Kojima
Kagawa Medical University Hospital ophthalmology
Outcome results
None listed